Lilly's MuSE optimizes trial design

Eli Lilly is enjoying improved dose/response relationships, better trial dose starting points, and the ability to simulate multiple trial endpoints, thanks to cloud computing. These cloud-based trial design improvements, in turn, are yielding fewer failed designs.

The improvements pushed the drug giant into the 28th spot on the InformationWeek 500 list of IT leaders. The magazine notes that Lilly's researchers use the public cloud to analyze pre-regulation discovery and development data; they continue to rely on secure in-house computing capabilities for assessing clinical data from drug candidate testing and trials.

Its cloud activities involve drug and disease modeling through a company effort called Modeling and Simulation Explorer, an interactive environment based on the Amazon cloud. The so-called MuSE effort lets drug developers extract and visualize model-derived information in real time, compressing days or weeks of researcher time into minutes, the magazine says, for help in selecting compounds and doses and optimizing study designs.

- check out the summary
- read some more details
- and here's the list

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.